不同方案治疗老年初治急性髓系白血病的临床疗效分析

Clinical efficacy of different regimens in the treatment of elderly patients with acute myeloid leukemia

目的:探讨不同方案治疗老年初治急性髓系白血病(AML)的临床疗效。方法:选取老年初治AML患者56例,随机分为观察组和对照组,每组28例。观察组给予地西他滨(DAC)联合CAG方案(阿柔比星+阿糖胞苷+粒细胞集落刺激因子)治疗,对照组给予IA方案(柔红霉素+阿糖胞苷)。比较两组患者的临床疗效、总生存时间(OS)及不良反应发生情况。结果:观察组总有效率(ORR)和OS明显高于对照组(P<0.05),骨髓抑制、继发感染及其他非血液学不良反应均明显低于对照组(P<0.05)。结论:DAC联合CAG方案治疗老年初治AML临床效果显著,能有效延长患者生存时间,减少不良反应的发生。

Objective:To investigate the clinical efficacy of different regimens in the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML).Methods:All 56 elderly patients with AML were randomly divided into study group and control group,with 28 cases in each group.The study group was treated with dexamethabine (DAC) combined with CAG (azubicin +cytarabine+granulocyte colony stimulating factor) and the control group was treated with IA (daunorubicin+cytarabine).The clinical efficacy,total survival time (OS) and adverse reactions were compared between the two groups.Results:The total effective rate (ORR) and OS of the study group were significantly higher than those of the control group ( P <0.05).Bone marrow suppression,secondary infection and other non-hematological adverse reactions were significantly lower than those of the control group ( P <0.05).Conclusion:DAC combined with CAG is effective in the treatment of AML in the elderly.It can effectively prolong the survival time of patients and reduce the occurrence of adverse reactions.